RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
Regulatory Agency Hub

Swissmedic Updates

The latest guidances, approvals, and safety alerts from Swissmedic, curated by automated regulatory intelligence.

REGULATORY UPDATE
Extended deadline for publishing officially mandated information materials on the electronic publication platform
Swissmedic • Published: Nov 12, 2026

Extends the deadline for publishing officially mandated information materials on the Swiss electronic publication platform, reducing near-term compliance…

View update →
REGULATORY UPDATE
Designer drugs: FDHA brings further psychoactive substances under control
Swissmedic • Published: Nov 10, 2026

Brings additional psychoactive “designer drugs” under Swiss control, expanding regulatory coverage to new substances with potential public-health and abuse…

safety
psychiatry
View update →
REGULATORY UPDATE
NAD+ supplements: When lifestyle products have criminal consequences
Swissmedic • Published: Nov 9, 2026

Highlights that misuse or illegal marketing of NAD+ “lifestyle” supplements may trigger criminal consequences, signaling a stricter enforcement posture against…

safety
labeling
+2
View update →
REGULATORY UPDATE
Publication eCTD v4.0 Implementation Guide Package v2.0
Swissmedic • Published: Nov 9, 2026

Provides implementation guidance for publishing and submitting regulatory dossiers using the eCTD v4.0 standard, aiming to standardize how companies format and…

manufacturing
quality
+3
View update →
REGULATORY UPDATE
Save the Date: Clinical Trials Symposium 2027
Swissmedic • Published: Nov 4, 2026

Announces a Swissmedic Clinical Trials Symposium 2027, likely serving as an informational forum for updates and discussion of current clinical trial…

clinical
safety
View update →
REGULATORY UPDATE
Submission of notifications of major changes via the Swissmedic Portal from 1 November 2026
Swissmedic • Published: Nov 2, 2026

Introduces the requirement to submit notifications of major changes through the Swissmedic Portal starting 1 November 2026.

View update →
REGULATORY UPDATE
Additional information on the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Swissmedic • Published: Nov 2, 2026

Clarifies additional information to support the Swiss parallel import pathway under TPA Art.

View update →
REGULATORY UPDATE
Modification of the “Form DMF”
Swissmedic • Published: Nov 1, 2026

Modification of the “Form DMF” indicates updates to the Drug Master File submission/administrative documentation framework that sponsors and DMF holders must…

quality
manufacturing
View update →
REGULATORY UPDATE
Update to the forms New authorisation of human medicinal products and Variations and extensions HAM
Swissmedic • Published: Nov 1, 2026

Updates the Swiss regulatory forms used for submitting new applications for human medicinal products and for submitting variations/extensions to authorization…

manufacturing
quality
+3
View update →
REGULATORY UPDATE
New strategic approach to minimizing animal testing in the development of medicinal products
Swissmedic • Published: Oct 20, 2026

Introduces a new regulatory strategy aimed at reducing reliance on animal testing during medicinal product development while still preserving scientifically…

safety
clinical
+1
View update →
REGULATORY UPDATE
GMP compliance by foreign manufacturers
Swissmedic • Published: Oct 9, 2026

Clarifies expectations for GMP compliance for manufacturing conducted by foreign manufacturers, indicating that Swiss requirements may be applied through…

manufacturing
quality
View update →
REGULATORY UPDATE
Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Swissmedic • Published: Oct 1, 2026

Clarifies or updates Swiss guidance on the conditions and documentation expectations for importing human medicinal products under Art. 14 para.

manufacturing
quality
+2
View update →
REGULATORY UPDATE
Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances
Swissmedic • Published: Oct 1, 2026

Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances, indicating that regulatory expectations…

manufacturing
quality
View update →
REGULATORY UPDATE
Revision of the Guidance document Authorisation Biosimilar
Swissmedic • Published: Oct 1, 2026

Revision of the Swissmedic guidance for authorisation of biosimilars may refine the regulatory expectations for demonstrating biosimilarity, including how…

immunology
manufacturing
+4
View update →
REGULATORY UPDATE
Swissmedic Portal Release – New Features Available from 23 September 2026
Swissmedic • Published: Sep 24, 2026

Swissmedic Portal updates will introduce new online functionality available from 23 September 2026, requiring regulated entities to prepare for changes in how…

manufacturing
quality
+3
View update →
REGULATORY UPDATE
I-SMI.TI.22e Notifications according to Article 41, MPLO
Swissmedic • Published: Sep 23, 2026

Defines or clarifies Swiss regulatory expectations for notifications submitted under Article 41 of the MPLO framework.

manufacturing
quality
+3
View update →
REGULATORY UPDATE
ElViS 2.0
Swissmedic • Published: Sep 4, 2026

ElViS 2.0 appears to be a Swiss regulatory update focused on a system/process commonly used for regulatory interactions, but the provided document content does…

View update →
REGULATORY UPDATE
swissdamed Webinar 10 November 2026
Swissmedic • Published: Sep 3, 2026

Webinar content likely provides an update on Swissmedic regulatory expectations, but the provided document text contains no substantive policy or procedural…

View update →
REGULATORY UPDATE
Simplification of applications for a change of status between main authorisation and export licence for veterinary medicinal products
Swissmedic • Published: Sep 1, 2026

Simplifies Swissmedic application procedures for changing a veterinary medicinal product’s status between its main authorisation and an export licence.

infectious_disease
oncology
+16
View update →
REGULATORY UPDATE
1 September 2026 – New: FAQ on Swissmedic Fees Ordinance
Swissmedic • Published: Sep 1, 2026

FAQ on Swissmedic Fees Ordinance provides interpretive clarification on how Swissmedic fees are assessed and managed under the Fees Ordinance.

manufacturing
quality
+3
View update →

Get Swissmedic alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.